Potential Oxidative Pathways of Catecholamines in the Formation of Lipid Peroxides and Genesis of Heart Disease

  • Pawan K. Singal
  • Robert E. Beamish
  • Naranjan S. Dhalla
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 161)


Results of clinical and experimental animal studies have shown that unusually high levels of catecholamines in the blood cause a variety of morphological and functional changes in the heart (1, 18, 22, 25, 28). The endogenous stores of adenine triphosphate and creatine phosphate are depleted (8, 25, 26) and mitochondrial structure-function is impaired (7, 15). Intracellular increase in calcium has been considered to be a determinant factor in this as well as in variety of other models of heart cell damage (8, 21). In this regard catecholamine-induced cardiomyopathy, has been shown to be accompanied by a significant increase in the myocardial calcium content (8,15) indicating changes in the membrane permeability. Strong evidence for the alterations in the permeability of sarcolemma due to isoproterenol treatment was provided by the intracellular diffusion of horseradish peroxidase, an extracellular protein tracer, following the drug injection (19).


Deficient Animal High Energy Phosphate Lipid Peroxide Formation Painful Stress Intracellular Diffusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    AVIADO, D.M., WNUCK, A.L. & DE BEER, E.J. Cardiovascular effects of sympathomimetic bronchodilators: epinephrine, ephedrine, pseudoephedrine, isoproterenol, methoxyphenamine and isoprophenamine. J. Pharmacol. Exp. Therap. 122, 406–417 (1958).Google Scholar
  2. 2.
    BARBER, A.A. & BERNHEIM, F. Lipid peroxidation: its measurement, occurrence and significance in animal tissue. Adv. Gerontal. Res. 2, 355–403 (1967).Google Scholar
  3. 3.
    BEAMISH, R.E., DHILLON, K.S., SINGAL, P.K. & DHALLA, N.S. Protective effect of sulfinpyrazone against catecholamine metabolite adrenochrome-induced arrhythmias. Am. Heart. J. 102, 149–152 (1981).PubMedCrossRefGoogle Scholar
  4. 4.
    CHANCE, B., SEISS, H. & BOVERIS, A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 59, 527–605 (1979).PubMedGoogle Scholar
  5. 5.
    COHEN, G. & HEIKKILA, R.E. The generation of hydrogen peroxide, superoxide radical and hydroxyl radical by 6-hydroxy-dopamine, dialuric acid and related cytotoxic agents. J. Biol. Chem. 249, 2447–2452 (1974).PubMedGoogle Scholar
  6. 6.
    DHALLA, N.S., YATES, J.C., LEE, S.L. & SINGH, A. Functional and subcellular changes in the isolated rat heart perfused with oxidized isoproterenol. J. Mol. Cell. Cardiol. 10, 31–41 (1978).PubMedCrossRefGoogle Scholar
  7. 7.
    DHALLA, N.S., SINGAL, P.K. & DHILLON, K. Mitochondrial functions and drug-induced heart disease. In: Drug-Induced Heart Disease, Vol. 5 (Bristow, M.R., ed.) North-Holland Biomedical Press, New York, 39–61 (1980).Google Scholar
  8. 8.
    FLECKENSTEIN, A., JANKE, T., DOERING, H.J. & PACHINGOER, O. Ca overload as the determinant factor in the production of catecholamine-induced myocardial lesions. Recent Advances in Studies on Cardiac Structure and Metabolism. 2, 455–466 (1973).PubMedGoogle Scholar
  9. 9.
    GRAHAM, D.G., TIFFANY, S.M., BELL, W.R. & GUTKNECTH, W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds toward C 1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644–653 (1978).PubMedGoogle Scholar
  10. 10.
    HUNTER, F.E., GEBICKI, J.M., HOFFSTEN, P.E., WEINSTEIN, J. & SCOTT, A. Swelling and lysis of rat liver mitochondria induced by ferrous ions. J. Biol. Chem. 238, 828–835 (1963).PubMedGoogle Scholar
  11. 11.
    JEQUIER, E. & PERRET, C. Urinary excretions of catecholamines and their main metabolites after myocardial infarction relationship to the clinical syndrome. Eur. J. Clin. Invest. 1, 77–82 (1970).PubMedCrossRefGoogle Scholar
  12. 12.
    LEVI, L. Neuroendocrinology of anxiety. In: Studies of Anxiety (Lader, M.H., ed.) Headley, London, P. 40 (1970).Google Scholar
  13. 13.
    MAY, H.E. & McCay, P.B. Reduced triphosphopyridine nucleotide oxidase-catalyzed alterations of membrane phospholipids. J. Biol. Chem. 243, 2296–2305 (1968).PubMedGoogle Scholar
  14. 14.
    MEERSON, F.Z. Disturbances of metabolism and cardiac function under the action of emotional painful stress and their prophylaxis. Basic. Res. Cardiol. 75, 479–500 (1980).PubMedCrossRefGoogle Scholar
  15. 15.
    NIRDLINGER, E.L. & Bramante, P.O. Subcellular myocardial ionic shifts and mitochondrial alterations in the course of isoproterenol-induced cardiomyopathy of the rat. J. Mol. Cell. Cardiol. 6, 49–60 (1974).PubMedCrossRefGoogle Scholar
  16. 16.
    PLAA, G.L. & WITSCHE, H. Chemicals, drugs and lipid peroxidation. Ann. Rev. Pharmacol. 16, 125–141 (1976).CrossRefGoogle Scholar
  17. 17.
    PLACER, Z.A., CUSHMAN, L.L. & JOHNSON, B.C. Estimation of product of lipid peroxidation (Malonyl dialdehyde) in biochemical systems. Anal. Biochem. 16, 359–365 (1966).PubMedCrossRefGoogle Scholar
  18. 18.
    RONA, G., CHAPPEL, C.I., BALAZS, T. & Gaudry, R. An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. A.M.A. Archiv. Pathol. 67, 443–455 (1959).Google Scholar
  19. 19.
    RONA, G., HUTTNER, I., BOUTET, M. & Badonnel, M.-C. Coronary microcirculatory factors in cardiac muscle cell injury. Recent Advances in Studies on Cardiac Structure and Metabolism. 12, 559–571 (1978).Google Scholar
  20. 20.
    SACHS, C. & JONSSON, G. Mechanisms of action of 6-hydroxy-dopamine. Biochem. Pharmacol. 24, 1–8 (1975).PubMedCrossRefGoogle Scholar
  21. 21.
    SINGAL, P.K., MATSUKUBO, M.P. & DHALLA, N.S. Calcium-related changes in the ultrastructure of mammalian myocardium. Br. J. Exp. Pathol. 60, 96–106 (1979).PubMedGoogle Scholar
  22. 22.
    SINGAL, P.K., DHILLON, K.S., BEAMISH, R.E. & DHALLA, N.S. Protective effect of zinc against catecholamine-induced myo-cardiac changes: Electrocardiographic and ultrastructural studies. Lab. Invest. 44, 426–433 (1981).Google Scholar
  23. 23.
    SINGAL, P.K., YATES, J.C., BEAMISH, R.E. & DHALLA, N.S. Influence of reducing agents on adrenochrome-induced changes in the heart. Arch. Pathol. Lab. Med. 105, 664–669 (1981).PubMedGoogle Scholar
  24. 24.
    SINGAL, P.K., DHILLON, K.S., BEAMISH, R.E., KAPUR, N. & DHALLA, N.S. Myocardial cell damage and cardiovascular changes due to I.V. infusion of adrenochrome in rats. Brit. J. Exp. Pathol. 63, 167–176 (1982).Google Scholar
  25. 25.
    SINGAL, P.K., KAPUR, N., DHILLON, K.S., BEAMISH, R.E. & DHALLA, N.S. Role of free radicals in catecholamine-induced cardiomyopathy. Can. J. Physiol. Pharmacol.(1982, in press).Google Scholar
  26. 26.
    TAKENAKA, F. & HUGUCHI, M. High-energy phosphate contents of subendocardium and supepicardium in the rat treated with isoproterenol and some other drugs. J. Mol. Cell. Cardiol. 6, 123–135 (1974).PubMedCrossRefGoogle Scholar
  27. 27.
    TAKEO, S., TAAM, G.M.L., BEAMISH, R.E. & DHALLA, N.S. Effect of adrenochrome on calcium accumulation by heart mitochondria. Biochem. Pharmacol. 30, 157–163 (1981).PubMedCrossRefGoogle Scholar
  28. 28.
    VALORI, C., THOMAS, M., SHILLINGFORD, J. Free noradrenaline and adrenaline excretion in relation to clinical syndromes following myocardial infarction. Am. J. Cardiol. 20, 605–609 (1967).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • Pawan K. Singal
    • 1
  • Robert E. Beamish
    • 1
  • Naranjan S. Dhalla
    • 1
  1. 1.Experimental Cardiology Section, Department of Physiology, Faculty of MedicineUniversity of ManitobaWinnipegCanada

Personalised recommendations